TICKERNERD
Menu
STESTEHealthcare · Medical Devices

STE Stock Forecast: STERIS Plc (Ireland) Price Predictions for 2026-2027

Last close, 4 Sept 2026
$225
−0.99% on the day

The 9 Wall Street analysts covering STERIS Plc (Ireland) hold a median 12-month price target of $270 — +20.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 3 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$22.1B
Ticker Nerd rank
86 / 100
Median analyst target
$270
Analysts covering
9
Revenue$1.5B+7.3% y/y
Operating income$285.9M
Net income$201.0M
Free cash flow$279.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.9%
1M
−3.5%
YTD
−10.9%
1Y
−7.2%
From 52W high
−15.9%
From 52W low
+12.6%
$199
$267
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

STE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores STERIS Plc (Ireland) on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Sept 2026
86 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
96
Value
96
Quality
86
Issuance
82
Growth
65
Revisions
63
Accruals
57
Momentum
54
Size
10

Volatility (96): The share price has been relatively steady.

Momentum (54): The shares have been drifting down relative to others.

Size (10): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

STE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on STE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$220$240$260$280Oct 25Jan 26Apr 26Jul 26STEHigh $280Median $270Low $232

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
6 Buy3 Hold0 Sell
Low $232Median $270High $280

The green dot is the last close — the median target sits +20.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
7 Aug 2026Piper SandlerReiteratesOverweight$270 → $275
7 Aug 2026UBSMaintainsBuy$275 → $270
28 July 2026UBSInitiatesBuy—
28 July 2026UBSInitiatesBuy$275
13 May 2026KeybancMaintainsOverweight—
13 May 2026KeybancMaintainsOverweight$291 → $269
8 Aug 2025Morgan StanleyMaintainsOverweight—
22 July 2025KeybancMaintainsOverweight—
15 July 2025Morgan StanleyUpgradeOverweight—
29 May 2025JefferiesInitiatesHold—
19 May 2025Morgan StanleyMaintainsEqual-Weight—
16 May 2025JMP SecuritiesMaintainsMarket Outperform—
15 May 2025Stephens & Co.ReiteratesOverweight—
12 May 2025Morgan StanleyMaintainsEqual-Weight—
10 Apr 2025JMP SecuritiesReiteratesMarket Outperform—
7 Apr 2025NeedhamReiteratesHold—
6 Feb 2025JMP SecuritiesReiteratesMarket Outperform—
6 Feb 2025Stephens & Co.ReiteratesOverweight—
3 Feb 2025Piper SandlerMaintainsOverweight—
18 Nov 2024JMP SecuritiesReiteratesMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

STE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, STERIS Plc (Ireland) returned −7.2% against +20.0% for the S&P 500, dividends included.

STE vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Oct 25Jan 26Apr 26Jul 26STES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

STE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.2%
Analysts raising
3
Analysts cutting
1
Fundamentals

STERIS Plc (Ireland) (STE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
28.2×

Cheaper than 28% of US stocks

Price / sales
3.7×

Cheaper than 35% of US stocks

Price / book
3.1×

Cheaper than 33% of US stocks

EV / EBITDA
14.4×

Cheaper than 24% of US stocks

Growth & margins
Revenue growth (YoY)
7.3%

Higher than 45% of US stocks

Earnings growth (YoY)
12.8%

Higher than 51% of US stocks

Gross margin
45.8%

Higher than 57% of US stocks

Operating margin
19.2%

Higher than 78% of US stocks

Net margin
13.3%

Higher than 75% of US stocks

Returns & dividend
Return on equity
11.4%

Higher than 66% of US stocks

Return on assets
6.8%

Higher than 84% of US stocks

Dividend yield
1.1%

Higher than 25% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

STERIS Plc (Ireland) (STE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • STERIS Plc (Ireland) has a market value of $22.1B and an enterprise value of $23.7B.

  • Revenue in the twelve months to 30 June 2026: $6.0B. The latest quarter grew 7.3% year on year.

  • Net income over the same four quarters: $808.1M, a 13.4% net margin.

  • Diluted earnings per share, trailing twelve months: $8.18.

  • Free cash flow in the twelve months to 30 June 2026: $925.6M.

  • STERIS Plc (Ireland) spent $340.4M on share buybacks and $247.0M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 97.5M.

  • Trailing P/E: 28.2×; forward P/E: 18.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.11%, paying out 31% of earnings.

  • STERIS Plc (Ireland) employs 17,937 people — $337K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Sept 2026

Data provided by Twelve Data

Peers

STE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
STESTERIS Plc (Ireland)$22.1B
86
ZBHZimmer Biomet Holdings, Inc.$19.6B
91
GEHCGE Healthcare Technologies, Inc.$31.8B
65
DXCMDexCom, Inc.$34.6B
98
PENPenumbra, Inc.$12.6B
76
GKOSGlaukos Corp.$10.6B
91
GMEDGlobus Medical, Inc.$10.6B
96

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own STERIS Plc (Ireland) — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest STE news & analysis

Steris (STE) Down 2.1% Since Last Earnings Report: Can It Rebound?

Zacks Investment Research · 4 Sept 2026negative

Steris reported earnings 30 days ago, and its stock has declined 2.1% since that report. The article examines whether the shares can rebound following the earnings release.

Why it matters — A STE watcher would care about this because the stock's post-earnings decline and the question of a potential rebound bear directly on the company's recent performance and near-term investor sentiment.

STERIS to Present at the Morgan Stanley Healthcare Conference

GlobeNewsWire · 1 Sept 2026neutral

STERIS plc announced it will participate in the Morgan Stanley Healthcare Conference in New York City on Tuesday, September 15, 2026. The announcement confirms the company's scheduled attendance at the industry event.

Why it matters — A STE watcher would care because conference participation gives management a platform to discuss the company's business with investors, though this announcement itself contains no new financial information.

Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales?

Zacks Investment Research · 21 Aug 2026neutral

STERIS is investing $600 million in a new chemistry center intended to boost capacity and efficiency, though the move brings higher spending and execution risks. The investment is being scaled up as part of the company's growth strategy.

Why it matters — A STE watcher would care because the $600 million chemistry center represents a significant capital commitment that could affect the company's capacity, efficiency, and financial performance.

Should Investors Buy STERIS as Growth Meets Reasonable Valuation?

Zacks Investment Research · 20 Aug 2026neutral

STERIS enters fiscal 2027 with solid growth, recurring healthcare demand and improved margins, according to a Zacks Investment Research report. However, tariffs and investment needs temper the valuation case as investors weigh the company's outlook.

Why it matters — A STE watcher would care because the report highlights both the company's positive growth drivers and the challenges that could affect its valuation as fiscal 2027 begins.

STERIS Q1 Earnings Call Highlights

MarketBeat · 9 Aug 2026positive

STERIS reported first-quarter fiscal 2027 revenue growth and higher earnings while maintaining its full-year outlook. The company also outlined a $600 million investment in a new chemistry manufacturing, research and distribution complex in North Carolina.

Why it matters — The news reflects ongoing business momentum and a significant expansion commitment for a STE watcher.

FAQ

Frequently asked questions about STE stock

What is the STE stock price forecast for 2026-2027?

The 9 Wall Street analysts covering STERIS Plc (Ireland) have a median 12-month price target of $270, with estimates ranging from $232 to $280. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is STE stock a buy right now?

Of the 9 analysts covering STERIS Plc (Ireland), 6 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks STERIS Plc (Ireland) 86 out of 100 across roughly 4,600 US stocks as at 3 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank STE?

As at 3 Sept 2026, STERIS Plc (Ireland) ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (96 of 100).

Will STE stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +20.0% from the last close, and Ticker Nerd's factor model ranks STERIS Plc (Ireland) 86 out of 100 as at 3 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the STE stock forecast for 2030?

No analyst covering STERIS Plc (Ireland) publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $232 to $280 over the next 12 months.

How has STE stock performed over the past year?

STERIS Plc (Ireland) returned -7.2% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does STERIS Plc (Ireland) do?

STERIS plc is a healthcare and life sciences company that provides infection prevention, contamination control, and procedural products and services. The company offers a broad portfolio that includes sterilizers, surgical tables, endoscopy accessories, cleaning chemistries, instrument and scope repair, laboratory testing, and outsourced reprocessing services.

What is the latest news on STE?

The most recent item we track (Zacks Investment Research, 4 Sept 2026): "Steris (STE) Down 2.1% Since Last Earnings Report: Can It Rebound?". Steris reported earnings 30 days ago, and its stock has declined 2.1% since that report. The article examines whether the shares can rebound following the earnings release.

Company

About STERIS Plc (Ireland).

STERIS plc is a healthcare and life sciences company that provides infection prevention, contamination control, and procedural products and services. The company offers a broad portfolio that includes sterilizers, surgical tables, endoscopy accessories, cleaning chemistries, instrument and scope repair, laboratory testing, and outsourced reprocessing services. Its operations support hospitals, ambulatory surgery centers, pharmaceutical and medical device manufacturers, and research laboratories. STERIS plc also serves biopharmaceutical and life sciences customers with contamination-control equipment, sterilization technologies, and related maintenance services. Through its mix of consumables, capital equipment, and recurring service offerings, the company plays an important role in helping healthcare and production environments maintain sterile conditions and support patient care across global markets.

CEO Mr. Daniel A. Carestio · 17,937 employees · United States · https://www.steris.com